Cumberland Pharmaceuticals Inc (CPIX)

Currency in USD
7.315
-0.235(-3.11%)
Real-time Data·
High dividend Yield
CPIX is not included in our AI-picked strategies. See which stocks are.
Fair Value
Day's Range
7.0277.530
52 wk Range
1.8508.230
Key Statistics
Prev. Close
7.55
Open
7.53
Day's Range
7.027-7.53
52 wk Range
1.85-8.23
Volume
6.76K
Average Volume (3m)
116.04K
1-Year Change
127.8816%
Book Value / Share
1.16
Fair Value
unlockUnlock
Fair Value Upside
unlockUnlock
CPIX Scorecardpro icon
Company’s Health
Unlock
Fair Value
Unlock Price
Fair Price
Upside
Analysts Sentiment
Currently not supported.
Members' Sentiments
Bearish
Bullish
ProTips
High return over the last year
Show more

Technical Analysis

Summary
Strong Sell
Sell
Neutral
Buy
Strong Buy
Sell
Technical Indicators
Strong Sell
Moving Averages
Neutral

Cumberland Pharmaceuticals Inc Earnings Call Summary for Q2/2026

  • Cumberland completed sale of commercial brands to Apotex for $100M upfront, $11M deferred, pivoting to development-stage biopharmaceutical company.
  • Q2 2026 operating loss of $3.1M, net loss of $4.1M; paid $22M special dividend ($1.50/share) and retired $5.2M credit line with proceeds.
  • Company projects cash runway exceeding five years with $50M+ in reserves; shares rose 8.22% to $7.77, then fell 8.11% after-hours to $7.14.
  • Ifetroban pipeline advancing: DMD FDA meeting expected fall 2026, systemic sclerosis and IPF interim results due 2026, oncology under evaluation.
  • Management emphasizes strategic shift from commercial to innovation-focused model; 99% shareholder approval reflects confidence in clinical execution strategy.
Last Updated: 05/08/2026, 07:34 am
Read Full Transcript

Earnings

Latest Release
04/08/2026
EPS / Forecast
-0.20 / --
Revenue / Forecast
166.45M / --
EPS Revisions
Last 90 days

Dividends

Payout Ratio
Payout ratio (TTM)
Earnings retained
EPS -0.50%
Dividend Yield
19.31%
Industry Median 2.33%
Annualised payout
1.50
Paid unevenly
5-Years Growth
-
Growth Streak

CPIX Income Statement

Compare CPIX to Peers and Sector

Metrics to compare
CPIX
Peers
Sector
Relationship
P/E Ratio
−35.3x−3.7x−0.4x
PEG Ratio
0.140.020.00
Price/Book
6.5x−0.6x2.6x
Price / LTM Sales
2.6x2.3x3.0x
Upside (Analyst Target)
-166.1%51.8%
Fair Value Upside
Unlock8.1%7.2%Unlock

Cumberland Pharmaceuticals Inc., a specialty pharmaceutical company, focuses on the acquisition, development, and commercialization of prescription products. The company offers Acetadote, an injection for the treatment of acetaminophen poisoning; Caldolor, an injection for the treatment of pain and fever; Kristalose, a prescription laxative oral solution for the treatment of constipation; Sancuso, a transdermal patch for the prevention of nausea and vomiting in patients receiving chemotherapy treatment; Vaprisol, an injection to raise serum sodium levels in hospitalized patients with euvolemic and hypervolemic hyponatremia; Vibativ, an injection for the treatment of certain bacterial infections, including hospital-acquired and ventilator-associated bacterial pneumonia, as well as complicated skin and skin structure infections; and Tacilia, an oral capsule for the treatment of H. pylori infection. It also develops ifetroban, a product candidate that has completed Phase II clinical trials for the treatment of cardiomyopathy associated with Duchenne muscular dystrophy, hepatorenal syndrome, portal hypertension, aspirin-exacerbated respiratory disease, systemic sclerosis, and idiopathic pulmonary fibrosis. It serves hospital acute care, gastroenterology, and oncology markets in the United States, China, South Korea, Russia, Mexico, Australia, and Saudi Arabia. The company has a strategic alliance agreement with WinHealth Pharma Group Co. Limited. Cumberland Pharmaceuticals Inc. was incorporated in 1999 and is headquartered in Nashville, Tennessee.

Employees
93

Ownership

Ownership Overview

Type
Common Stock Held% of Shares OutstandingMarket Value
Mutual Funds & ETFs
1.02M6.83%7.73M
Other Institutional Investors
2.41M16.08%18.19M
Public Companies & Retail Investors
11.55M77.09%87.21M
Total
14.98M100.00%113.12M

Top Holders

Holder
% of holding
Shares Held
Date Reported
Value (In 1,000s)
Integrated Core Strategies (US) LLC4.00%598,6344,520
Ikarian Capital, LLC3.69%553,1534,176

People Also Watch

2.65
TDIC
+1.15%
1.3750
QUCY
-5.17%
0.220
CREG
+9.40%
3.360
HCWB
-2.04%
0.383
GAME
+6.36%

FAQ

What Is the Cumberland (CPIX) Stock Price Today?

The Cumberland stock price today is 7.315 USD.

What Stock Exchange Does Cumberland Trade On?

Cumberland is listed and trades on the Nasdaq Stock Exchange.

What Is the Stock Symbol for Cumberland?

The stock symbol for Cumberland is "CPIX."

Does Cumberland Pay Dividends? What’s The Current Dividend Yield?

The Cumberland dividend yield is 19.87%.

What Is the Cumberland Market Cap?

As of today, Cumberland market cap is 109.600M USD.

What Is Cumberland's Earnings Per Share (TTM)?

The Cumberland EPS (TTM) is -0.497.

When Is the Next Cumberland Earnings Date?

Cumberland will release its next earnings report on 04/08/2026.

From a Technical Analysis Perspective, Is CPIX a Buy or Sell?

Based on moving averages and other technical indicators, the daily buy/sell signal is Strong Buy.

How Many Times Has Cumberland Stock Split?

Cumberland has split 0 times.

How Many Employees Does Cumberland Have?

Cumberland has 93 employees.

What is the current trading status of Cumberland (CPIX)?

As of 06/08/2026, Cumberland (CPIX) is trading at a price of 7.315 USD, with a previous close of 7.550 USD. The stock has fluctuated within a day range of 7.027 USD to 7.530 USD, while its 52-week range spans from 1.850 USD to 8.230 USD.

What Is the CPIX Premarket Price?

CPIX's last pre-market stock price is 7.380 USD. The pre-market share volume is 430.000, and the stock has decreased by -0.170, or -2.250%.

What Is the CPIX After Hours Price?

CPIX's last after hours stock price is 7.530 USD, the stock has decreased by -0.020, or -0.260%.
Risk Disclosure: Trading in financial instruments and/or cryptocurrencies involves high risks including the risk of losing some, or all, of your investment amount, and may not be suitable for all investors. Prices of cryptocurrencies are extremely volatile and may be affected by external factors such as financial, regulatory or political events. Trading on margin increases the financial risks.
Before deciding to trade in financial instrument or cryptocurrencies you should be fully informed of the risks and costs associated with trading the financial markets, carefully consider your investment objectives, level of experience, and risk appetite, and seek professional advice where needed.
Fusion Media would like to remind you that the data contained in this website is not necessarily real-time nor accurate. The data and prices on the website are not necessarily provided by any market or exchange, but may be provided by market makers, and so prices may not be accurate and may differ from the actual price at any given market, meaning prices are indicative and not appropriate for trading purposes. Fusion Media and any provider of the data contained in this website will not accept liability for any loss or damage as a result of your trading, or your reliance on the information contained within this website.
It is prohibited to use, store, reproduce, display, modify, transmit or distribute the data contained in this website without the explicit prior written permission of Fusion Media and/or the data provider. All intellectual property rights are reserved by the providers and/or the exchange providing the data contained in this website.
Fusion Media may be compensated by the advertisers that appear on the website, based on your interaction with the advertisements or advertisers.
© 2007-2026 - Fusion Media Limited. All Rights Reserved.